Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Metastatic melanoma.

W Sun¹, L M Schuchter

¹University of Pennsylvania Cancer Center, Hematology-Oncology Division, 16 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104-4283, USA.

Current Treatment Options in Oncology

|June 12, 2002

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Corrigendum to 'Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma': [Annals of Oncology 34 (2023) 806-812].

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Same author

Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2023

Same author

Vogt-Koyanagi-Harada-like syndrome in the setting of combined anti-PD1/anti-CTLA4 therapy.

Clinical and experimental dermatology·2021

Same author

Molecular diversity and distribution of anammox community in sediments of the Dongjiang River, a drinking water source of Hong Kong.

Journal of applied microbiology·2013

Same author

An introduction to clinical practice guideline for Chinese undergraduates in stomatology.

European journal of dental education : official journal of the Association for Dental Education in Europe·2013

Same author

Improving job satisfaction of Chinese doctors: the positive effects of perceived organizational support and psychological capital.

Public health·2013

Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026

Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026

Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026

Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026

Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026

Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026

See all related articles

Metastatic melanoma survival is poor, with no standard treatment. Chemotherapy, immunotherapy, and biochemotherapy show varied responses, but new treatments like vaccines are under investigation.

Area of Science:

Oncology
Medical Research

Background:

Metastatic melanoma has a median survival of 8.5 months, with no defined standard treatment.
Current options include observation, surgery, chemotherapy (dacarbazine, cisplatin, temozolomide), and clinical trials.

Purpose of the Study:

To review current treatment options for metastatic melanoma.
To discuss the efficacy and limitations of various chemotherapeutic and immunotherapeutic agents.
To highlight emerging treatment strategies.

Main Methods:

Literature review of chemotherapeutic agents and combination regimens.
Analysis of response rates and survival data for different treatments.
Discussion of immunotherapies and biochemotherapy studies.

Related Experiment Videos

Main Results:

Dacarbazine has a 15-20% response rate; temozolomide has a 20% response rate.
Combination regimens like Dartmouth and CVD show response rates of 10-25%.
Immunotherapies (IFN-alfa, IL-2) yield 15-20% responses; biochemotherapy shows high response rates but unclear survival benefit and significant toxicity.

Conclusions:

Metastatic melanoma treatment remains challenging with limited efficacy of current standard therapies.
Biochemotherapy shows promise but requires further investigation due to toxicity and unclear survival impact.
New approaches, including vaccines and cytokine combinations, are under investigation.